HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder	Not yet recruiting	Phase 2 / Phase 3	2026-05-27		NCT07608224

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
First Affiliated Hospital Xi'an Jiaotong University	142
Peking University First Hospital	225
RenJi Hospital	264
The First Affiliated Hospital of Air Force Medicial University	24
The First Affiliated Hospital with Nanjing Medical University	319
The Second Affiliated Hospital of Kunming Medical University	33
Tianjin Medical University Second Hospital	50
Tongji Hospital	276
West China Hospital	359

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.